Phase 2 N=71 Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=90 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Prostate Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale
Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
Phase 2 N=195 Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
Castration Resistant Metastatic Prostate Cancer
Primary: Progression Free Survival as Measured by Number of Months Until Clinical or Radiographic Progression — 5.62; 5.72 months
Phase 2 N=18 Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
Androgen Receptor Positive · Estrogen Receptor Negative · HER2/Neu Negative
Primary: Response Rate (Complete Response or Partial Response) — 1; 1; 2; 12 Participants
Phase 2 N=114 A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
Prostate Cancer
Primary: Change in Sexual Activity Score of Psychosexual Daily Questionnaire (PDQ-4) — 0.04; 0.45; -0.02; 0.12 units on a scale
Phase 2 N=59 Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Advanced Epithelial Ovarian · Recurrent Epithelial Ovarian · Fallopian Tube
Primary: Overall Response Rate — 1.7 percentage of participants with response
Phase 2 N=24 Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
Invasive Breast Carcinoma · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: RCB Status — 4; 6; 8; 6 Participants
Phase 2 N=136 Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
ER+ and AR+ Breast Cancer
Primary: Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects — 16; 15 participants
Phase 2 N=62 A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
Prostate Cancer
Primary: Number of Patients Who Achieve a PSA ≤ 4ng/mL After Seven Months of Protocol Treatment in Each Arm — 16; 32 Participants — p=0.87
Phase 2 N=45 COMbination of Bipolar Androgen Therapy and Nivolumab
Castration-resistant Prostate Cancer · Metastatic Prostate Cancer · Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy + Nivolumab — 18 Participants
Phase 2 N=118 Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Prostate Cancer
Primary: Combined pCR or MRD Rate [Part 1] — 12; 12 Participants
Phase 2 N=36 RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
Prostate Cancer
Primary: Overall Response Rate — 6 percentage of patients
Phase 2 N=30 Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
Prostate Cancer · Recurrent Prostate Carcinoma · Stage IV Prostate Adenocarcinoma
Primary: Number of Participants With Change in PSA Response — 2; 0 Participants
Phase 2 N=27 Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Outcome Correspondence to Imaging Results With Fluorine-18 Fluorocholine PET/CT — 100; 100; 100; 0 %PET-positive cases in a given PSA range
Phase 2 N=64 AASUR in High Risk Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Biochemical Failure — 12; 52 Participants
Phase 2 N=96 RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT) — 9; 5; 4; 2 Participants
Phase 2 N=45 Radiation and Androgen Ablation for Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Biochemical Failure Free-rate (BFFR) Associated With the Combined Hypofractionated Dose Regimen and Androgen Deprivation Therapy (ADT). — 0 progression events
N/A N=25 Androgen Effects in HIV-infected Women
HIV Infection
Primary: Lean Body Mass — 1.8; 0.8 kilograms — p=0.04
Phase 2 N=36 Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Prostate Adenocarcinoma
Primary: Percent of Patients With a Prostate-specific Antigen (PSA) Decline of at Least 50% Below Baseline PSA50 Response Rate — 14 Participants
Phase 2 N=35 RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Primary: Biochemical Response Rate — 0 participants
Phase 2 N=118 Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Primary: Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population — 33.3 Percentage of participants
Phase 1 N=105 CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
Hypogonadism
Primary: Percent Change in Bone Mineral Density (BMD) According to rs700518 Polymorphism in the CYP19A1 Gene — 3.69; 4.13; 3.82; 0.38 percent change — p=<0.05
Phase 2 N=33 Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
Recurrent Prostate Cancer
Primary: Patients With PSA <4 ng/mL at the End of the Study — 17 participants
Phase 2 N=72 Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
Metastatic Castrate-resistant Prostate Cancer · Adenocarcinoma, Prostate
Primary: Number of Patients Who Experience Dose Limiting Toxicities by Dose Level — 0; 0; 0; 0 Participants
Phase 2 N=19 Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage III Prostate Cancer
Primary: Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria — 5; 3 Participants — p=0.46
Phase 3 N=62 PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate
Healthy
Primary: Prostate Tissue DHT Concentrations After Treatment — 4.05; 4.26; 2.99; 3.88 ng/g
Phase 2 N=60 5-Alpha Reductase and Anabolic Effects of Testosterone
Male Hypogonadism · Muscle Atrophy · Sarcopenia
Primary: 1 Repetition Maximum (1-RM) Strength Testing — 129.1; 109.4; 137.2; 118.8 kg — p=<0.001
Phase 2 N=37 Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients With Undetectable PSA (Prostate-Specific Antigen) at 1 Year — 54.54 percentage of participants
Phase 2 N=66 Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
Prostate Cancer
Primary: Number of Participants With a Pathology Tumor Stage of Less Than or Equal to Prostate Cancer Stage at Which the Tumor is Confined to the Prostate (pT2) — 24; 8…